| | Clinical Factors | Early TLR(-) | Early TLR(+) | P | | | (354 patients) | (40 patients) | |
| | Age (years old) | 65.3±10.4 | 66.9±11.0 | 0.369 | | BMI (kg/m2) | 24.8±2.9 | 23.9±3.3 | 0.073 | | Male sex, n (%) | 265 (74.9) | 24 (60.0) | 0.068 | | Previous PCI, n (%) | 38 (10.7) | 10 (25.0) | 0.018 | | Diabetes mellitus, n (%) | 114 (32.2) | 19 (47.5) | 0.078 | | Hypertension, n (%) | 246 (69.5) | 29 (72.5) | 0.833 | | CRF, n (%) | 137 (38.7) | 25 (62.5) | 0.006 | | Dyslipidemia, n (%) | 225 (63.6) | 23 (57.5) | 0.562 | | Current smoking, n (%) | 95 (26.8) | 9 (22.5) | 0.689 | | FHx of CAD, n (%) | 44 (12.4) | 6 (15.0) | 0.807 | | LV ejection fraction (%) | 60.3±8.3 | 57.3 ± 10.6 | 0.119 | | Clinical diagnosis | | | 0.127 | | (i) Silent ischemia, n (%) | 21 (5.9) | 0 (0) | | | (ii) Stable angina, n (%) | 209 (59.0) | 23 (57.5) | | | (iii) Unstable angina, n (%) | 71 (20.1) | 7 (17.5) | | | (iv) STEMI, n (%) | 22 (6.2) | 2 (5.0) | | | (v) NSTEMI, n (%) | 31 (8.8) | 8 (20.0) | | | Multi Vessel disease, n (%) | 255 (72.0) | 31 (77.5) | 0.576 |
| | Laboratory tests | | | |
| | WBC (109/L) | 6.9±2.4 | 6.5±1.7 | 0.332 | | Hemoglobin (g/dl) | 13.6±1.8 | 12.9±2.0 | 0.018 | | Creatinine(mg/dl) | 1.05±0.44 | 1.39±1.60 | 0.183 | | GFR(ml/min/1.73m2) | 70.8±24.0 | 57.5±28.2 | 0.015 | | Total cholesterol (mg/dl) | 157±38 | 159±45 | 0.845 | | Triglyceride (mg/dl) | 140±86 | 120±66 | 0.193 | | LDL (mg/dl) | 97±35 | 94±44 | 0.666 | | HDL (mg/dl) | 42±11 | 44±12 | 0.302 | | CRP (mg/dl) | 0.40±1.17 | 0.37±0.84 | 0.870 |
| | Medication at discharge | | | |
| | (i) Aspirin, n (%) | 353 (99.7) | 40 (100.0) | 1.000 | | (ii) Clopidogrel, n (%) | 353 (99.7) | 40 (100.0) | 1.000 | | (iii) DAPT, n (%)# | 352 (99.4) | 40 (100.0) | 1.000 | | (iv) Beta blocker, n (%) | 251 (70.9) | 28 (70.0) | 1.000 | | (v) Statin, n (%) | 337 (95.2) | 39 (97.5) | 1.000 | | (vi) CCB, n (%) | 75 (21.2) | 11 (27.5) | 0.418 | | (vii) ACEI, n (%) | 85 (24.0) | 16 (40.0) | 0.035 | | (viii) ARB, n (%) | 134 (37.9) | 19 (47.5) | 0.237 |
| | Medication at first follow-up | | | |
| | (i) Aspirin, n (%) | 351 (99.2) | 40 (100.0) | 1.000 | | (ii) Clopidogrel, n (%) | 346 (97.7) | 39 (97.5) | 1.000 | | (iii) DAPT, n (%)# | 343 (96.9) | 39 (97.5) | 1.000 | | (iv) Beta blocker, n (%) | 266 (75.1) | 28 (70.0) | 0.451 | | (v) Statin, n (%) | 352 (99.4) | 40 (100.0) | 1.000 | | (vi) CCB, n (%) | 79 (22.3) | 8 (20.0) | 0.842 | | (vii) ACEI, n (%) | 36 (10.2) | 8 (20.0) | 0.106 | | (viii) ARB, n (%) | 145 (41.0) | 13 (32.5) | 0.395 |
| | Medication at second follow-up | | | |
| | (i) Aspirin, n (%) | 324 (91.5) | 38 (95.0) | 0.758 | | (ii) Clopidogrel, n (%) | 300 (84.7) | 37 (92.5) | 0.239 | | (iii) DAPT, n (%)# | 272 (76.8) | 35 (87.5) | 0.159 | | (iv) Beta blocker, n (%) | 256 (72.3) | 25 (62.5) | 0.200 | | (v) Statin, n (%) | 349 (98.6) | 39 (97.5) | 0.476 | | (vi) CCB, n (%) | 68 (19.2) | 9 (22.5) | 0.674 | | (vii) ACEI, n (%) | 28 (7.9) | 7 (17.5) | 0.070 | | (viii) ARB, n (%) | 137 (38.7) | 13 (32.5) | 0.495 |
| | Lesion factors | Early TLR(-) | Early TLR(+) | | | | (886 lesions) | (58 lesions) | |
| | Treated coronary location | | | 0.854 | | (i) LAD, n (%) | 411 (46.4) | 28 (48.3) | | | (ii) LCX, n (%) | 218 (24.6) | 16 (27.6) | | | (iii) RCA, n (%) | 255 (28.8) | 14 (24.1) | | | Bifurcation lesion, n (%) | 308 (34.8) | 25 (43.1) | 0.204 | | Calcified lesion | | | 0.004 | | (i) None, n (%) | 451 (51.2) | 26 (44.8) | | | (ii) Mild, n (%) | 155 (17.6) | 4 (6.9) | | | (iii) Moderate, n (%) | 114 (12.9) | 7 (12.1) | | | (iv) Severe, n (%) | 161 (18.3) | 21 (36.2) | | | Tortuous lesion | | | 0.465 | | (i) None, n (%) | 819 (92.9) | 56 (96.6) | | | (ii) Mild, n (%) | 24 (2.7) | 0 (0) | | | (iii) Moderate, n (%) | 26 (2.9) | 2 (3.4) | | | (iv) Severe, n (%) | 13 (1.5) | 0 (0) | | | Angulation lesion, n (%) | | | 0.305 | | (i) None (<45°), n (%) | 821 (93.3) | 56 (98.2) | | | (ii) Moderate (45°<90°), n (%) | 37 (4.2) | 1 (1.8) | | | (iii) Extreme n (>90°), n (%) | 22 (2.5) | 0 (0) | | | Thrombus in lesion, n (%) | 29 (3.3) | 0 (0) | 0.291 | | Ostial lesion, n (%) | 169 (19.1) | 14 (24.1) | 0.390 | | Ulceration, n (%) | 2 (0.2) | 3 (5.2) | 0.002 | | Aneurysm, n (%) | 10 (1.1) | 0 (0) | 1.000 | | Lesion type | | | 0.142 | | (i) A, n (%) | 92 (10.4) | 8 (13.8) | | | (ii) B1, n (%) | 214 (24.2) | 8 (13.8) | | | (iii) B2, n (%) | 52 (5.9) | 7 (12.1) | | | (iv) C, n (%) | 499 (56.3) | 34 (58.6) | | | Type B2/C lesion, n (%) | 551 (64.3) | 41 (71.9) | 0.305 | | Reference vessel diameter (mm) | 2.92±0.51 | 2.78±0.66 | 0.100 | | Lesion length (mm) | 27.7±17.1 | 28.8±19.4 | 0.647 | | Pre-procedure MLD (mm) | 0.74±0.50 | 0.68±0.49 | 0.385 | | Pre-procedure DS (%) | 74.7±15.7 | 75.9±15.5 | 0.569 | | Post-procedure MLD, in- stent (mm) | 2.49±0.43 | 2.26±0.48 | <0.001 | | Post-procedure MLD, in-segment (mm) | 2.13±0.51 | 1.85±0.57 | <0.001 | | Post-procedure DS, in- stent (mm) | 11.4±8.1 | 18.0±11.2 | <0.001 | | Post-procedure DS, in-segment (mm) | 21.0±11.3 | 29.9±13.6 | <0.001 |
|
|
TLR, target lesion revascularization; BMI, body mass index; kg, kilogram; PCI, percutaneous coronary intervention; CRF, chronic renal failure; FHx, family history; CAD, coronary artery disease; LV, left ventricle; STEMI, ST-elevation myocardial infarction; NSTEMI, non-ST-elevation myocardial infarction; WBC, white blood cell; GFR, glomerular filtration rate; LDL, low density lipoprotein cholesterol; HDL, high density lipoprotein cholesterol; CRP, C-reactive protein; DAPT, dual antiplatelet therapy; CCB, calcium channel blockers; ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin II receptor blockers; LAD, left anterior descending; LCX, left circumflex; RCA, right coronary artery; MLD, minimal lumen diameter; DS, diameter stenosis.
# DAPT: combination of aspirin and clopidogrel.
|
